Based on clinical trials and post-marketing data to date, there has been no signal of increased risk of serious arrhythmias or sudden cardiac death with Wegovy, though pharmacovigilance continues
Participants also had to have at least one other underlying conditionsuch as obesity, hypertension or heart disease
Daily weight changes can be misleading Weight can shift by one or two kilos due to water levels, hormones, digestion, or activity
At the highest Zepbound dose of 15 mg weekly, results showed: Average weight loss: 22.5% of body weight Breaking down the success rates: 96% lost at least 5% of body weight 89% lost at least 10% of body weight 78% lost at least 15% of body weight 63% lost at least 20% of body weight For someone weighing 220 pounds, losing 22.5% means dropping about 50 pounds to reach 170 pounds
Lab results should be interpreted in consultation with a qualified healthcare professional
More serious but less common adverse effects include pancreatitis, gallbladder disease, and potential thyroid C-cell tumours (observed in animal studies, though the clinical relevance in humans remains uncertain)